The integration of AI into drug submission and approval processes signifies a shift towards more efficient pharmaceutical ...

Q3 2024 Earnings Call Transcript November 6, 2024 UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.55, ...

Cipla’s FDA-compliant facilities and its investments in US-based units place it in a strong position to weather potential ...

Election Day is just about here, marking an end to the unpredictable ride that has been the 2024 presidential race following ...

The Pharma & Biotech market had a relatively muted month. There were a number of companies that experienced strong share ...

RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent ...

Collegium Pharmaceutical Inc (COLL) reports a 17% increase in total net product revenues and outlines strategic plans for growth in the ADHD market.

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

I don’t foresee major policy-driven changes impacting Indian pharma exports to the US ... Will the act influence Cipla’s manufacturing strategy? The trend of manufacturing closer to the US market ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

For market entry strategy for drugs in Japan, understanding the submission requirements is as crucial as the documentation itself. The submission dossier must be meticulously prepared, containing all ...

Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ...